Thursday, April 16

    CALIFORNIA: Revolution Medicines said on April 13 that its experimental pancreatic cancer drug daraxonrasib significantly extended survival in a pivotal late-stage trial, marking one of the strongest reported results to date for a targeted medicine in previously treated metastatic pancreatic ductal adenocarcinoma. The company said patients in the overall study population lived a median of 13.2 months on the once-daily oral drug,…

    News

    Health

    Technology

    Sports

    Lifestyle